A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback